This GBM cell-specific purine blockade strategy is facilitated by the fact that about half of GBMs bear homozygous MTAP deletions, making them deficient in adenine salvage and uniquely susceptible to this therapeutic strategy. This evidence concerns the gene MTAP and glioblastoma.